HuGE Literature Finder
|
Records 1-10
Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial.
Acta oncologica (Stockholm, Sweden) 2018 May 1-6. Brøndum Line, Alsner Jan, Sørensen Brita Singers, Maare Christian, Johansen Jørgen, Primdahl Hanne, Evensen Jan Folkvard, Kristensen Claus Andrup, Andersen Lisbeth Juhler, Overgaard Jens, Eriksen Jesper Gr |
The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
The pharmacogenomics journal 2017 Jul . Magnes T, Melchardt T, Hufnagl C, Weiss L, Mittermair C, Neureiter D, Klieser E, Rinnerthaler G, Roesch S, Gaggl A, Greil R, Egle |
Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
Oral oncology 2016 Dec 63 38-43. Fernández-Mateos J, Seijas-Tamayo R, Mesía R, Taberna M, Pastor Borgoñón M, Pérez-Ruiz E, Adansa Klain J C, Vázquez Fernández S, Del Barco Morillo E, Lozano A, González Sarmiento R, Cruz-Hernández J J, |
FCGR Polymorphisms Influence Response to IL-2 in Metastatic Renal Cell Carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Oct . Erbe Amy K, Wang Wei, Goldberg Jacob, Gallenberger Mikayla, Kim KyungMann, Carmichael Lakeesha, Hess Dustin, Mendonca Eneida A, Song Yiqiang, Hank Jacquelyn A, Cheng Su-Chun, Signoretti Sabina, Atkins Michael, Carlson Alexander, Mier James W, Panka David J, McDermott David F, Sondel Paul |
IGKC and Fc?R genotypes and humoral immunity to HER2 in breast cancer.
Immunobiology 2013 Aug . Pandey JP, Kistner-Griffin E, Black L, Namboodiri AM, Iwasaki M, Kasuga Y, Hamada GS, Tsugane S |
Pathway-based analysis of genetic susceptibility to cervical cancer in situ: HLA-DPB1 affects risk in Swedish women.
Genes and immunity 2011 Dec 12 (8): 605-14. Ivansson E L, Juko-Pecirep I, Erlich H A, Gyllensten U |
Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer.
BMC cancer 2011 Nov 11 (1): 1. Dahan L, Norguet E, Etienne-Grimaldi MC, Formento JL, Gasmi M, Nanni I, Gaudart J, Garcia S, Ouafik L, Seitz JF, Milano G |
Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Sep 29 (25): 3419-26. Maubec Eve, Petrow Peter, Scheer-Senyarich Isabelle, Duvillard Pierre, Lacroix Ludovic, Gelly Julien, Certain Agnès, Duval Xavier, Crickx Béatrice, Buffard Valérie, Basset-Seguin Nicole, Saez Pierre, Duval-Modeste Anne-Bénédicte, Adamski Henri, Mansard Sandrine, Grange Florent, Dompmartin Anne, Faivre Sandrine, Mentré France, Avril Marie-Françoi |
Fc?R polymorphisms and clinical outcome in colorectal cancer patients receiving passive or active antibody treatment.
International journal of oncology 2010 Dec 37 (6): 1599-606. Wang Biyun, Kokhaei Parviz, Mellstedt Håkan, Liljefors Mar |
A Large-scale genetic association study of esophageal adenocarcinoma risk.
Carcinogenesis 2010 Jul 31 (7): 1259-63. Liu Chen-Yu, Wu Michael C, Chen Feng, Ter-Minassian Monica, Asomaning Kofi, Zhai Rihong, Wang Zhaoxi, Su Li, Heist Rebecca S, Kulke Matthew H, Lin Xihong, Liu Geoffrey, Christiani David |
- Page last reviewed:Jul 30, 2019
- Page last updated:Dec 12, 2019
- Content source: